RaeSedo, Inc. has been selected to present its groundbreaking approach to asthma treatment at the prestigious 2024 ATS Respiratory Innovation Summit. This recognition underscores RaeSedo’s
RaeSedo Inc., a spin-out of the University of Arizona developing novel therapies for asthma, is pleased to announce the award of a Phase 2 Small Business Technology
Surfactant Protein-A (SP-A) plays a crucial role in asthma, but genetic variation can lead to dysfunction. Researchers investigated a specific genetic change at position 223 in SP-A2, finding that individuals with the major variant (223Q) had better lung function, reduced inflammation, and improved asthma control. In mouse models and cells from asthmatic participants, they also showed that SP-A 223Q peptides had anti-inflammatory effects, suggesting their potential as therapeutic agents for asthma.
Drs. Monica Kraft and Julie Ledford received SSTR funding for a Phase I proposal to develop new, short peptide derivatives and mimetics of the active
The “sharks” ultimately invested in Monica Kraft, MD, and Julie Ledford, PhD, for their pitch on a new, inhaled therapeutic for the treatment of asthma and potentially even COPD, cystic fibrosis and pneumonia. The duo was presented with a check for $10,000 at the end of the competition.
Copyright © 2024 | RaeSedo